Response endpoints
| Primary endpoint | GIST | DDLPS | UPS | |||
| N (n=9) | N+I (n=9) | N (n=12) | N+I (n=12) | N (n=12) | N+I (n=12) | |
| Confirmed response rate | 0 (0%) | 0 (0%) | 1 (8.3%) | 2 (16.6%) | 1 (8.3%) | 2 (16.6%) |
| Secondary endpoint | GIST | DDLPS | UPS | |||
| N (n=10) | N+I (n=11) | N (n=15) | N+I (n=14) | N (n=14) | N+I (n=15) | |
| Clinical benefit rate | 4 (40%) | 6 (54.5%) | 10 (66.6%) | 11 (78.6%) | 4 (28.6%) | 8 (53.3%) |
| Progression-free survival (months) | 1.5 (95% CI 1.3–Inf) | 2.9 (95% CI 1.4–Inf) | 4.6 (95% CI 3.2–Inf) | 5.5 (95% CI 2.8–Inf) | 1.4 (95% CI 1.4–14.2) | 2.7 (95% CI 1.5–Inf) |
| Overall survival (months) | 9.1 (95% CI 4.9–Inf) | 12.2 (95% CI 6.0–Inf) | 8.1 (95% CI 6.8–Inf) | 14.6 (95% CI 9.1–Inf) | 6.6 (95% CI 2.4–Inf) | 15.2 (95% CI 5.1–Inf) |
DDLPS, dedifferentiated liposarcoma; GIST, gastrointestinal stromal tumor; UPS, undifferentiated pleomorphic sarcoma.